2 active not recruiting, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
Follow Platinum-Sensitive Ovarian Carcinoma: new trials by email Literature Review of Platinum-Sensitive Ovarian Carcinoma trials Research Report on Platinum-Sensitive Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-04-26 | 2026-11-05 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 61 | 2019-12-04 | 2026-08-26 |
Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2) · Breast Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1)
Adnexal Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Neoplasms (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Gonadal Disorders (2) · Ovarian Diseases (2)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Bevacizumab (1) · Biopsy (1) · Disulfides (1) · Immunoglobulin G (1) · olaparib (1) · pembrolizumab (1) · talazoparib (1) · tremelimumab (1)
National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (1)
United States (3)
A P Chen (1) · Emese Zsiros (1) · Sarah F Adams (1)
U10CA180868 (1)